Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

8.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
RNA Interference01:23

RNA Interference

28.6K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.6K
RNA Interference01:23

RNA Interference

7.8K
7.8K
MicroRNAs01:22

MicroRNAs

4.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

24.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease.

Molecular biomedicine·2026
Same author

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assays.

Frontiers in immunology·2026
Same author

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy.

Molecular imaging and biology·2026
Same author

RNA editing for the treatment of alpha-1 antitrypsin deficiency.

Nucleic acids research·2026
Same author

Butyrophilin 3A/2A1-independent activation of human Vγ9Vδ2 γδ T cells by bacteria.

PNAS nexus·2025
Same author

Alternative Structural Lipids Impact mRNA-Lipid Nanoparticle Morphology, Stability, and Activity.

Molecular pharmaceutics·2025

Related Experiment Video

Updated: Mar 26, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

8.1K

Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.

Sonke Svenson1, Roy I Case1, Roderick O Cole1

  • 1Cerulean Pharma Inc. , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.

Molecular Pharmaceutics
|February 3, 2016
PubMed
Summary

Polymeric nanopharmaceuticals (PNPs) offer a promising solution for delivering small interfering RNA (siRNA) therapeutics. These novel nanoparticles enhance stability and tumor targeting, enabling effective gene silencing with minimal side effects.

Keywords:
PLGAPLK1cancer therapydrug conjugationpolymeric nanoparticlessiRNA delivery

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

841

Related Experiment Videos

Last Updated: Mar 26, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

8.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

841

Area of Science:

  • Biotechnology
  • Nanomedicine
  • RNA Therapeutics

Background:

  • Small interfering RNA (siRNA) therapeutics offer high specificity but face challenges like short half-lives, cytokine responses, and poor cellular uptake.
  • Current siRNA delivery systems often exhibit inadequate tumor penetration and efficacy.
  • Nanoparticle formulation can improve siRNA stability and enable site-specific delivery via the enhanced permeability and retention (EPR) effect.

Purpose of the Study:

  • To develop and evaluate novel polymeric nanopharmaceuticals (PNPs) for enhanced siRNA delivery and gene silencing in tumors.
  • To assess the stability, pharmacokinetics, tumor accumulation, and biological activity of PLGA-based PNPs.
  • To determine the safety profile of these PNPs at therapeutic doses.

Main Methods:

  • Formation of PNPs using poly(lactic-co-glycolic acid) (PLGA) conjugated to siRNA via a cleavable disulfide linker.
  • Incorporation of polyethylene glycol (PEG) for improved pharmacokinetics, a cation for siRNA complexation, and poly(vinyl alcohol) (PVA) for stabilization.
  • In vivo evaluation of PNP circulation time, tumor accumulation, gene knockdown efficacy, and safety parameters (body weight, blood counts, serum chemistry, cytokine levels).

Main Results:

  • PNPs demonstrated prolonged circulation and uniform tumor accumulation, leveraging the EPR effect.
  • Effective and prolonged tumor-specific gene silencing was achieved.
  • PNPs showed an excellent safety profile, with no adverse effects observed at doses significantly higher than the effective dose.

Conclusions:

  • PLGA-based PNPs are a promising platform for durable siRNA delivery and gene silencing in tumors.
  • These nanopharmaceuticals overcome key limitations of traditional siRNA therapeutics, offering enhanced stability and targeted delivery.
  • The developed PNPs present a safe and effective strategy for advancing siRNA-based cancer therapies.